MEDICLIN AG (MED.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:MED - DE0006595101 - Common Stock
3.76 EUR
+0.02 (+0.53%)
Taking everything into account, MED scores 6 out of 10 in our fundamental rating. MED was compared to 32 industry peers in the Health Care Providers & Services industry. While MED belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on MED.
1. Profitability
1.1 Basic Checks
- In the past year MED was profitable.
- MED had a positive operating cash flow in the past year.
- In multiple years MED reported negative net income over the last 5 years.
- MED had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- MED's Return On Assets of 3.85% is fine compared to the rest of the industry. MED outperforms 65.63% of its industry peers.
- With a decent Return On Equity value of 14.15%, MED is doing good in the industry, outperforming 71.88% of the companies in the same industry.
- The Return On Invested Capital of MED (7.06%) is better than 68.75% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for MED is below the industry average of 7.02%.
- The 3 year average ROIC (3.46%) for MED is below the current ROIC(7.06%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.85% | ||
| ROE | 14.15% | ||
| ROIC | 7.06% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
1.3 Margins
- MED's Profit Margin of 4.40% is fine compared to the rest of the industry. MED outperforms 78.13% of its industry peers.
- In the last couple of years the Profit Margin of MED has grown nicely.
- MED has a Operating Margin of 8.52%. This is in the better half of the industry: MED outperforms 78.13% of its industry peers.
- In the last couple of years the Operating Margin of MED has grown nicely.
- The Gross Margin of MED (84.08%) is better than 84.38% of its industry peers.
- MED's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.52% | ||
| PM (TTM) | 4.4% | ||
| GM | 84.08% |
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MED is creating some value.
- The number of shares outstanding for MED remains at a similar level compared to 1 year ago.
- MED has about the same amout of shares outstanding than it did 5 years ago.
- Compared to 1 year ago, MED has an improved debt to assets ratio.
2.2 Solvency
- MED has an Altman-Z score of 1.59. This is a bad value and indicates that MED is not financially healthy and even has some risk of bankruptcy.
- MED has a worse Altman-Z score (1.59) than 65.63% of its industry peers.
- The Debt to FCF ratio of MED is 9.63, which is on the high side as it means it would take MED, 9.63 years of fcf income to pay off all of its debts.
- With a Debt to FCF ratio value of 9.63, MED perfoms like the industry average, outperforming 53.13% of the companies in the same industry.
- MED has a Debt/Equity ratio of 1.69. This is a high value indicating a heavy dependency on external financing.
- With a Debt to Equity ratio value of 1.69, MED is not doing good in the industry: 65.63% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.69 | ||
| Debt/FCF | 9.63 | ||
| Altman-Z | 1.59 |
ROIC/WACC1.46
WACC4.84%
2.3 Liquidity
- MED has a Current Ratio of 1.93. This is a normal value and indicates that MED is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 1.93, MED belongs to the top of the industry, outperforming 90.63% of the companies in the same industry.
- MED has a Quick Ratio of 1.89. This is a normal value and indicates that MED is financially healthy and should not expect problems in meeting its short term obligations.
- The Quick ratio of MED (1.89) is better than 93.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.89 |
3. Growth
3.1 Past
- MED shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 414.18%, which is quite impressive.
- MED shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 20.79% yearly.
- Looking at the last year, MED shows a small growth in Revenue. The Revenue has grown by 3.40% in the last year.
- The Revenue has been growing slightly by 2.19% on average over the past years.
EPS 1Y (TTM)414.18%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%7.67%
Revenue 1Y (TTM)3.4%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%7.96%
3.2 Future
- The Earnings Per Share is expected to grow by 20.09% on average over the next years. This is a very strong growth
- MED is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.42% yearly.
EPS Next Y62.2%
EPS Next 2Y28.31%
EPS Next 3Y20.09%
EPS Next 5YN/A
Revenue Next Year5.05%
Revenue Next 2Y3.88%
Revenue Next 3Y3.42%
Revenue Next 5YN/A
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 5.08 indicates a rather cheap valuation of MED.
- Based on the Price/Earnings ratio, MED is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
- The average S&P500 Price/Earnings ratio is at 27.30. MED is valued rather cheaply when compared to this.
- With a Price/Forward Earnings ratio of 5.52, the valuation of MED can be described as very cheap.
- Based on the Price/Forward Earnings ratio, MED is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.04, MED is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.08 | ||
| Fwd PE | 5.52 |
4.2 Price Multiples
- 93.75% of the companies in the same industry are more expensive than MED, based on the Enterprise Value to EBITDA ratio.
- Based on the Price/Free Cash Flow ratio, MED is valued cheaper than 87.50% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.84 | ||
| EV/EBITDA | 2.9 |
4.3 Compensation for Growth
- MED's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- MED has a very decent profitability rating, which may justify a higher PE ratio.
- MED's earnings are expected to grow with 20.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.08
PEG (5Y)0.24
EPS Next 2Y28.31%
EPS Next 3Y20.09%
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 1.13%, MED has a reasonable but not impressive dividend return.
- Compared to an average industry Dividend Yield of 1.57, MED has a dividend in line with its industry peers.
- With a Dividend Yield of 1.13, MED pays less dividend than the S&P500 average, which is at 1.92.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.13% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y28.31%
EPS Next 3Y20.09%
FRA:MED (1/13/2026, 7:00:00 PM)
3.76
+0.02 (+0.53%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-04 2025-11-04
Earnings (Next)03-26 2026-03-26
Inst Owners0.96%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap178.60M
Revenue(TTM)797.34M
Net Income(TTM)35.05M
Analysts80
Price Target5.87 (56.12%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.13% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)22.34%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)6.4%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.08 | ||
| Fwd PE | 5.52 | ||
| P/S | 0.22 | ||
| P/FCF | 3.84 | ||
| P/OCF | 1.85 | ||
| P/B | 0.72 | ||
| P/tB | 0.8 | ||
| EV/EBITDA | 2.9 |
EPS(TTM)0.74
EY19.68%
EPS(NY)0.68
Fwd EY18.13%
FCF(TTM)0.98
FCFY26.04%
OCF(TTM)2.04
OCFY54.13%
SpS16.79
BVpS5.21
TBVpS4.7
PEG (NY)0.08
PEG (5Y)0.24
Graham Number9.32
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.85% | ||
| ROE | 14.15% | ||
| ROCE | 9.1% | ||
| ROIC | 7.06% | ||
| ROICexc | 9.61% | ||
| ROICexgc | 10.05% | ||
| OM | 8.52% | ||
| PM (TTM) | 4.4% | ||
| GM | 84.08% | ||
| FCFM | 5.83% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
ROICexc(3y)4.47%
ROICexc(5y)3.03%
ROICexgc(3y)4.72%
ROICexgc(5y)3.22%
ROCE(3y)4.46%
ROCE(5y)3.03%
ROICexgc growth 3Y64.29%
ROICexgc growth 5Y26.18%
ROICexc growth 3Y68.25%
ROICexc growth 5Y27.23%
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
F-Score8
Asset Turnover0.88
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.69 | ||
| Debt/FCF | 9.63 | ||
| Debt/EBITDA | 3.49 | ||
| Cap/Depr | 96.09% | ||
| Cap/Sales | 6.29% | ||
| Interest Coverage | 3.18 | ||
| Cash Conversion | 80.47% | ||
| Profit Quality | 132.66% | ||
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.89 | ||
| Altman-Z | 1.59 |
F-Score8
WACC4.84%
ROIC/WACC1.46
Cap/Depr(3y)56.34%
Cap/Depr(5y)45.08%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)414.18%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%7.67%
EPS Next Y62.2%
EPS Next 2Y28.31%
EPS Next 3Y20.09%
EPS Next 5YN/A
Revenue 1Y (TTM)3.4%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%7.96%
Revenue Next Year5.05%
Revenue Next 2Y3.88%
Revenue Next 3Y3.42%
Revenue Next 5YN/A
EBIT growth 1Y281.51%
EBIT growth 3Y73.21%
EBIT growth 5Y21.8%
EBIT Next Year143.72%
EBIT Next 3Y33.62%
EBIT Next 5YN/A
FCF growth 1Y196.83%
FCF growth 3Y-17.96%
FCF growth 5Y7.78%
OCF growth 1Y96.85%
OCF growth 3Y-0.57%
OCF growth 5Y2.97%
MEDICLIN AG / MED.DE FAQ
What is the ChartMill fundamental rating of MEDICLIN AG (MED.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to MED.DE.
Can you provide the valuation status for MEDICLIN AG?
ChartMill assigns a valuation rating of 9 / 10 to MEDICLIN AG (MED.DE). This can be considered as Undervalued.
Can you provide the profitability details for MEDICLIN AG?
MEDICLIN AG (MED.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for MED stock?
The Price/Earnings (PE) ratio for MEDICLIN AG (MED.DE) is 5.08 and the Price/Book (PB) ratio is 0.72.
What is the financial health of MEDICLIN AG (MED.DE) stock?
The financial health rating of MEDICLIN AG (MED.DE) is 4 / 10.